Skip to main content
Download PDF
  • Dépicit Androgénique
  • Recommandations
  • Published:

Diagnostic, traitement et surveillance de l’hypogonadisme de survenue tardive chez l’homme: Recommandations officielles de l’International Society for the Study of the Aging Male (ISSAM) et commentaires

Investigation, treatment and monitoring of lateonset hypogonadism in males: the official guidelines of the International Society for the Study of the Aging Male (ISSAM), with comments

Andrologie volume 13, pages 331–347 (2003)Cite this article

Resume

Les altérations hormonales de l’homme vieillissant représentent un sujet d’intérêt croissant, aux enjeux importants liés au développement attendu de cette population d’hommes âgés de plus de 50 ans.

Les préoccupations actuelles concernent essentiellement le déclin des androgènes chez l’homme vieillissant (androgen decline in the aging male: «ADAM»), ou déficit partiel en androgènes de l’homme vieillissant (partial androgen deficiency of the aging male: «PADAM»), communément appelée «andropause» en France. Si les connaissances au sujet du déficit androgénique de l’homme âgé ont progressé, elles sont encore incomplètes, parfois confuses, et certains points concernant le traitement androgénique substitutif restent controversés.

C’est pourquoi l’International Society for the Study of the Aging Male (ISSAM) a jugé opportun de faire le point sous la forme d’une série de recommandations pratiques et officielles concernant le diagnostic, le traitement et la surveillance de l’hypogonadisme de survenue tardive chez l’homme.

Le but de ce travail est de présenter ces recommandations internationales récentes, sous la forme de leur traduction française, et de les commenter.

Abstract

There is increasing interest in the subject of hormone changes in the aging male, which is likely to become particularly important with the expected growth in the population of men over 50.

The main concerns at present are androgen decline in the aging male (ADAM), or partial androgen deficiency of the aging male (PADAM), commonly known as the andropause. Although progress has been made in our knowledge of androgen deficiency in the aging male, it is still incomplete and sometimes confusing, and some aspects of androgen replacement therapy remain controversial.

The International Society for the Study of the Aging Male (ISSAM) therefore felt it was a good time to review the current situation by publishing a series of practical and official guidelines concerning the diagnosis, treatment and monitoring of late-onset hypogonadism in males.

The aim of this study is to present and discuss the French translation of these recent international guidelines.

References

  1. ALEXANDER G.M., SWERDLOFF R.S., WANG C., DAVIDSON T., MCDONALD V., STEINER B.: Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm. Behav., 1998, 33: 85–94.

    Article  PubMed  CAS  Google Scholar 

  2. AMMUS S.S.: The role of androgens in the treatment of hematologic disorders. Adv. Intern. Med., 1989, 34: 191–208.

    PubMed  CAS  Google Scholar 

  3. ARLT W., CALLIES F., VAN VLIJMEN J.C. et al.: Dehydroepiandrosterone replacement in women with adrenal insuffiency. N. Engl. J. Med., 1999, 341: 1013–1020.

    Article  PubMed  CAS  Google Scholar 

  4. ATKINSON L.E., CHANG Y.L. et al.: Long-term experience with testosterone replacement through scrotal skin. In: Nieschlag E., Behre H.M. eds. Testosterone, Action, Deficiency, Substitution. Berlin, Springer Verlag, 1998: 365–438.

    Google Scholar 

  5. BAULIEU E.E., THOMAS G., LEGRAIN S. et al.: Dehydroepiandrosterone (DHEA), DHEA sulphate, and aging: contribution of DHEAge study to sociobiomedical issue. Proc. Natl. Acad. Sci. U.S.A., 2000, 97: 4279–4284.

    Article  PubMed  CAS  Google Scholar 

  6. BEHRE H.M., KLIESCH S., LEIFKE E., LINK T.M., NIESCHLAG E.: Long term effect of testosterone therapy on bone density in hypogonadal men. J. Clin. Endocrinol. Metab., 1997, 82: 2386–2390.

    Article  PubMed  CAS  Google Scholar 

  7. CONTE-DEVOIX B.: Le diagnostic des déficits en hormone de croissance (GH) chez l’adulte. Med. Ther., 2002, 4: 33–35.

    Google Scholar 

  8. COOPER D.: Subclinical hypothyroidism. N. Engl. J. Med., 2001, 345: 260–265.

    Article  PubMed  CAS  Google Scholar 

  9. COSTA P.: Adénome prostatique, hormones et androgénothérapie. Andrologie, 2002, 12: 133–135.

    Article  Google Scholar 

  10. DELHEZ M., HANSENNE M., LEGROS J.J.: Andropause and psychopathology: minor symptoms rater than pathological ones. Psychoneuroendocrinology, 2003, (sous presse).

  11. DRINKA P.J., JOCHEN A.L., CUISINIER M., BLOOM R., RUDMAN I., RUDMAN D.: Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J. Am. Geriatr. Soc., 1995, 43: 899–901.

    PubMed  CAS  Google Scholar 

  12. ENGLISH K.M., STEEDS R.P., JONES T.H., DIVER M.J., CHANNER K.S.: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. A randomized, double-blind, placebo-controlled study. Circulation, 2000, 102: 1906–1911.

    PubMed  CAS  Google Scholar 

  13. FLAM T.: Traitement androgénique substitutif et cancer prostatique. Andrologie, 2002, 12: 136–137.

    Article  Google Scholar 

  14. GARDNER F.H., NATHAN D.G., PIOMELLI S., CUMMINS J.F.: The erythrocytemic effects of androgens. Br. J. Haematol., 1968, 14: 611–615.

    Article  PubMed  CAS  Google Scholar 

  15. GARRY P.J., GOODWI J.S., HUNT W.C.: Iron status and anemia in the elderly. J. Am. Geriatr. Soc., 1983, 31: 389–399.

    PubMed  CAS  Google Scholar 

  16. HAJJAR R.R., KAISER F.E., MORLEY J.E.: Outcomes of long-term testosterone replacement therapy in older hypogonadal males: a retrospective study. J. Clin. Endocrinol. Metab., 1997, 82: 3793–3796.

    Article  PubMed  CAS  Google Scholar 

  17. HEINEMANN L.A.J., ZIMMERMAN T., VERMEULEN A., THIEL C., HUMMEL W.: A new aging male symptoms rating scale. Aging Male, 1999, 2: 105–114.

    Article  Google Scholar 

  18. HIBBERTS N.A., HOWELL A.E., RANDALL V.A.: Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J. Endocrinol., 1998, 156: 59–65.

    Article  PubMed  CAS  Google Scholar 

  19. JAMIN C.: HDL-cholestérol et stéroïdes sexuels: la fin d’un mythe? Lettre Gynécol., 2001, 258: 44–46.

    Google Scholar 

  20. JOCKENHOVEL F., VOGEL E., REINHARDT W., REINWEIN D.: Effects of various modes of androgen substitution therapy on erythropoiesis. Eur. J. Med. Res., 1997, 2: 293–298.

    PubMed  CAS  Google Scholar 

  21. KAUFMAN J.M.: Androgens, bone metabolism and osteoporosis. In: Oddens B., Vermeulen A. eds. Androgens and the Aging male. Carnforth, UK, Parthenon Publishing, 1996: 39–63.

    Google Scholar 

  22. KENNEDY B.J., GILBERTSON A.S.: Increased erythropoiesis induced by androgenic-hormone therapy. N. Engl. J. Med., 1957, 256: 719.

    PubMed  CAS  Google Scholar 

  23. KENNY A.M., PRESTWOOD K.M., RAISZ L.G.: Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol and hematocrit in men over age 70 with low testosterone levels. Endocr. Res., 2000, 26: 153–168.

    Article  PubMed  CAS  Google Scholar 

  24. KENNY A.M., PRESTWOOD K.M., GRUMAN C.A., MARCELLO K.M., RAISZ L.G.: Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A. Biol. Sci. Med. Sci., 2001, 56: M266–272.

    PubMed  CAS  Google Scholar 

  25. KIM C.Y., BUVAT J., CARSON C.C. et al.: Endocrine and metabolic aspect including treatment. In: Jardin A., Wagner G., Khoury S., Giuliano F., Padma-Nathan H., Rosen, R. eds. Erectile dysfunction. 1st international consulation on erectile dysfunction, July 1–3, 1999, Paris. Plymouth, Health Publication Ltd, Plymbridge Distributors, 2000: 207–240.

    Google Scholar 

  26. KRAUSS D.J., TAUB H.A., LANTINGA L.J., DUNSKY M.H., KELLY C.M.: Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J. Urol., 1991, 146: 1566–1570.

    PubMed  CAS  Google Scholar 

  27. LEGROS J.J., DELHEZ M.: Détection de la déficience androgénique chez l’homme de plus de 50 ans: utilisation d’une version française du test ADAM. Med. Hyg., 2002, 60: 1490–1495.

    Google Scholar 

  28. LUBOSHITZKY R., AVIV A., HEFETZ A. et al.: Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J. Clin. Endocrinol. Metab., 2002, 87: 3394–3398.

    Article  PubMed  CAS  Google Scholar 

  29. MATSUMOTO A.M., SANDBLOM R.E., SCHOENE R.B. et al.: Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives, and sleep. Clin. Endocrinol., 1985, 22: 713–721.

    Article  CAS  Google Scholar 

  30. MEIKLE AW. A permeation-enhanced non-scotal testosterone transdermal system for the treatment of male hypogonadism. In: Nieschlag E., Behre H.M. eds. Testosterone, Action, Deficiency, Substitution. Berlin, Springer Verlag, 1998: 390–422.

    Google Scholar 

  31. MORALES A., LUNENFELD B.: Androgen replacement therapy in aging male with secondary hypogonadism. Draft recommendations for endorment by ISSAM. Aging Male, 2001, 4: 151–162.

    Article  CAS  Google Scholar 

  32. MORALES A, LUNENFELD B.: Standards, guidelines and recommandations of the International Society for the Study of the Aging Male (ISSAM). Investigation, treatment and monitoring of late-onset hypogonadism in males. Official Recommandations of ISSAM. Aging Male, 2002, 5: 74–86.

    Article  PubMed  CAS  Google Scholar 

  33. MORALES A. Androgen replacement therapy and prostate safety. Eur. Urol., 2002, 41: 113–120.

    Article  PubMed  CAS  Google Scholar 

  34. MORLEY J.E., CHARLTON E., PATRICK P. et al.: Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism, 2000, 49: 1239–1242.

    Article  PubMed  CAS  Google Scholar 

  35. MORLEY J.E., PERRY H.M. 3RD.: Androgen deficiency in aging men: role of testosterone replacement therapy. J. Lab. Clin. Med., 2000, 135: 370–378.

    Article  PubMed  CAS  Google Scholar 

  36. MORRIS F.K., LOY V.E. et al.: Hemoglobin concentration as determined by a methemoglobin method. Am. J. Clin. Pathol., 1956, 26: 1450–1455.

    PubMed  CAS  Google Scholar 

  37. Report of the National Institute on Aging Advisory Panel on testosterone replacement in men. J. Clin. Endocrinol. Metab., 2001, 86: 4611–4614.

    Google Scholar 

  38. ROGER M., LAHLOU N.: Le déficit androgénique lié à l’âge: du diagnostic biologique au traitement substitutif. Andrologie, 2002, 12: 138–148.

    Article  Google Scholar 

  39. ROSNER W.: Errors in the measurement of plasma free testosterone. J. Clin. Endocrinol. Metab., 1997, 82: 2014–2015.

    PubMed  CAS  Google Scholar 

  40. SCHIAVI R.C., WHITE D., MANDELI J.: Pituitary-gonadal function during sleep in headline aging male. Psychoneuroendocrinology, 1992, 17: 599–609.

    Article  PubMed  CAS  Google Scholar 

  41. SHAHIDI N.T.: Androgens and erythropoiesis. N. Engl. J. Med., 1973, 289: 72–80.

    Article  PubMed  CAS  Google Scholar 

  42. SIH R., MORLEY J.E., KAISER F.E., PERRY H.M. 3RD, PATRICK P., ROSS C.: Testosterone replacement in older hypogonadal men: a 12 month randomized controlled study. J. Clin. Endocrinol. Metab., 1997, 82: 1661–1667.

    Article  PubMed  CAS  Google Scholar 

  43. SVETEC D.A., CANBY E.D., THOMPSON I.M., SABANEGH E.S. JR.: The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfonction. J. Urol., 1997, 158: 1775–1777.

    Article  PubMed  CAS  Google Scholar 

  44. TENOVER J.S.: Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab., 1992, 75: 1092–1098.

    Article  PubMed  CAS  Google Scholar 

  45. TENOVER J.S.: Androgen administration to aging men. Endocrinol. Metab. Clin. North Am., 1994, 23: 877–892.

    PubMed  CAS  Google Scholar 

  46. TREMBLAY R.R., MORALES A.: Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male, 1998, 1: 213–218.

    Article  Google Scholar 

  47. URBAN R.J., BODENBURG Y.H., GILKINSON C., FOWWORTH J., COGGAN A.R., WOLFE R.R.: Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am. J. Physiol., 1995, 269: E820-E826.

    PubMed  CAS  Google Scholar 

  48. VERMEULEN A.: Commentary to the article-low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoproteins in normoglycemic men. J. Clin. Endocrinol. Metab., 1998, 83: 1822–1823.

    Article  PubMed  CAS  Google Scholar 

  49. VERMEULEN A., VERDONCK L., KAUFMAN J.L.: A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab., 1999, 84: 3666–3672.

    Article  PubMed  CAS  Google Scholar 

  50. WINTERS S.J., KELLEY D.E., GOODPASTER B.: The analog free testosterone assay: are the results in men clinically useful? Clin. Chem., 1998, 44: 2178–2182.

    PubMed  CAS  Google Scholar 

  51. ZEITZER J., DANIELS J.E., DUFFY J.F. et al.: Do plasma melatonin concentrations decline with age? Am. J. Med., 1999, 107: 432–436.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Urologie, Hôpital Edouard Herriot, Lyon, France

    Béatrice Cuzin

  2. Service d’Urologie, Hôpital Bicêtre, Le Kremlin Bicêtre, France

    François Guiliano

  3. Service de Gynécologie-Obstétrique, CHU Bichat-Claude Bernard, Paris, France

    Christian Jamin

  4. Service Universitaire d’Endocrinologie, CHU Sart-Tilman, Liège, Belgique

    Jean-Jacques Legros

  5. Département de Médecine de la Reproduction, Hôpital Edouard Herriot, Lyon, France

    Hervé Lejeune

  6. Service d’Andrologie, Hôpital Calmette, CHRU Lille, France

    Marc Rigot

  7. Laboratoire de Biologie Hormonale, Hôpital Saint-Vincent-de-Paul, Paris, France

    Marc Roger

Authors
  1. Béatrice Cuzin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. François Guiliano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Jamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Jacques Legros
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hervé Lejeune
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marc Rigot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marc Roger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hervé Lejeune.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cuzin, B., Guiliano, F., Jamin, C. et al. Diagnostic, traitement et surveillance de l’hypogonadisme de survenue tardive chez l’homme: Recommandations officielles de l’International Society for the Study of the Aging Male (ISSAM) et commentaires. Androl. 13, 331–347 (2003). https://doi.org/10.1007/BF03035201

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03035201

Mots-clés

Key words

Basic and Clinical Andrology

ISSN: 2051-4190